Company profile · Biotech & medical
PharmaEngine
智擎生技製藥股份有限公司 · 4162
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
PharmaEngine engages in new drug development, focusing on cancer treatments.[1]
The company's approved drug ONIVYDE is a liposomal formulation of camptothecin anticancer drug developed using nanotechnology, and is used for metastatic pancreatic cancer patients.[2]
The investigational new drug project PEP07 is a cell damage regulation enzyme inhibitor currently in the first clinical trial stage, targeting acute myeloid leukemia.[2]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$23m | -18.3% | -89.9% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$22m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | PharmaEngine, Inc. |
|---|---|
| Chinese name | 智擎生技製藥股份有限公司 |
| Stock code | 4162 (TPEx) |
| Industry | Biotech & medical |
| Founded | 12 Aug 2002 |
| Listed | 18 Sep 2012 |
| Paid-in capital | NT$1.4bn |
| Chairman | 許璋瑤 |
| President | 王宏仁 |
| Headquarters | 11F, 10 Minsheng E. Road, Sec. 3, Taipei 104 Taiwan Taipei, Taiwan |
| Website | https://www.pharmaengine.com |
| Official business description | 新藥開發 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- MOPS 公司基本資料 智擎生技製藥股份有限公司 · mops · retrieved 04 Nov 2026
- Annual report 2025 (Chinese), business scope · annual_report · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list